483 related articles for article (PubMed ID: 15187209)
1. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
Yoo BK; Triller DM; Yong CS; Lodise TP
Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
3. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
Bhavnani SM; Andes DR
Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
5. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
Blondeau JM; Tillotson G
Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
7. Role of gemifloxacin in community-acquired pneumonia.
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
[TBL] [Abstract][Full Text] [Related]
8. Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.
Zhang L; Wang R; Falagas ME; Chen LA; Liu YN
Chin Med J (Engl); 2012 Feb; 125(4):687-95. PubMed ID: 22490497
[TBL] [Abstract][Full Text] [Related]
9. Gemifloxacin: a new fluoroquinolone.
Blondeau JM; Missaghi B
Expert Opin Pharmacother; 2004 May; 5(5):1117-52. PubMed ID: 15155113
[TBL] [Abstract][Full Text] [Related]
10. Gemifloxacin for community-acquired pneumonia.
Lode HM; Schmidt-Ionas M; Stahlmann R
Expert Opin Investig Drugs; 2008 May; 17(5):779-86. PubMed ID: 18447602
[TBL] [Abstract][Full Text] [Related]
11. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
12. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
Ball P; Mandell L; Patou G; Dankner W; Tillotson G
Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
[TBL] [Abstract][Full Text] [Related]
13. Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae.
Morrissey I; Tillotson G
J Antimicrob Chemother; 2004 Feb; 53(2):144-8. PubMed ID: 14729748
[TBL] [Abstract][Full Text] [Related]
14. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae.
Owens RC; Bhavnani SM; Ambrose PG
Diagn Microbiol Infect Dis; 2005 Jan; 51(1):45-9. PubMed ID: 15629228
[TBL] [Abstract][Full Text] [Related]
15. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.
Jivcu C; Gotfried M
Int J Chron Obstruct Pulmon Dis; 2009; 4():291-300. PubMed ID: 19684863
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies of garenoxacin.
Takagi H; Tanaka K; Tsuda H; Kobayashi H
Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
[TBL] [Abstract][Full Text] [Related]
18. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
File TM; Tillotson GS
Expert Rev Anti Infect Ther; 2004 Dec; 2(6):831-43. PubMed ID: 15566328
[TBL] [Abstract][Full Text] [Related]
19. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.
Leonard SN; Kaatz GW; Rucker LR; Rybak MJ
J Antimicrob Chemother; 2008 Dec; 62(6):1305-10. PubMed ID: 18801920
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
